retatrutide peptide 20mg (RETA) Retatrutide Canada (20mg) | Laboratory

Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes

CrossRef The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B Jiaxin Han, Lianxin Xu, Yuqin Li, Ziling Wang, Minghui Zeng, Jieru Gao, Yuqiang Mi, Wentao Kuai, Huiling Xiang, Liang Xu Frontiers in Immunology .2026;[Epub] CrossRef Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)id Heejoon Jang, Won Kim Clinical and Molecular Hepatology .2026

This article examines the safety considerations, potential risks, and evidence-based alternatives for postpartum weight management that protect both maternal and infant health

Retatrutide has shown significant weight loss potential in clinical trials due to its triple hormone action

Data were derived from de-identified electronic health record (EHR) extracts including medication orders, patient demographics, and longitudinal weight measurements

People who are most likely to benefit from a GLP-1 RA are sometimes the least likely [archived link] to have access to them